一个I期研究,以确定Capivasertib在健康男性参与者的绝对生物可用性和吸收,分布,新陈代谢和分泌
Claire Miller1, Martin Wild1, Zhoupeng Zhang1
1Clinical Pharmacology and Quantitative Pharmacology, BioPharmaceuticals R&D (C.M.), Drug Metabolism and Pharmacokinetics, Oncology R&D (M.W.), Global Medicines Development, Oncology R&D (R.S., D.S.), Integrated Bioanalysis, BioPharmaceuticals R&D (C.B.), and Pharmaceutical Sciences, R&D (R.A.B., M.G.), AstraZeneca, Cambridge, United Kingdom; Drug Metabolism and Pharmacokinetics, Oncology R&D (Z.Z.) and Clinical Pharmacology and Quantitative Pharmacology, BioPharmaceuticals R&D (J.D.), AstraZeneca, Waltham, Massachusetts; Quotient Sciences Ltd, Ruddington, Nottingham, United Kingdom (S.S.); and Clinical Pharmacology and Quantitative Pharmacology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (M.C.).
这项研究确定了强有力的AKT抑制剂capivasertib的药理动力学. 绝对生物利用率为28.6%,排泄物中95.1%的剂量恢复,为其临床发展提供了信息.
科学领域:
- 药理学 药理学是指药理学的学科.
- 临床药理学 临床药理学
- 药物代谢和药理动力学
背景情况:
- 卡比瓦塞尔蒂布是一种强效和选择性的AKT血清/三氨酸激酶抑制剂.
- 了解其药理动力学特征对于临床开发至关重要.
研究的目的:
- 为了确定capivasertib在健康男性中的绝对生物可用性.
- 为了表征capivasertib.的吸收,分布,新陈代谢和分泌 (ADME).
- 为了确定capivasertib的代谢物及其对分泌的贡献.
主要方法:
- 一个开放的,单中心的,健康男性的第一阶段研究.
- 第1部分:单次口服剂量 (400毫克) 和静脉注射 [14C]-微剂量.
- 第2部分:洗后单次口服 [14C]capivasertib (400 mg) 剂量.
主要成果:
- 估计capivasertib的绝对生物利用率为28.6%.
- 在168小时的排泄物中,放射性的平均恢复率为95.1% (50.4%便,44.7%尿液).
- M11 (AZ14142143) 是一种不活跃的葡萄糖合物,是血和排泄物中最丰富的代谢物.
结论:
- 这项研究描述了人体中的capivasertib的药理动力学,质量平衡和代谢命运.
- 这些发现支持capivasertib.目前正在进行的临床开发.
- 直接的葡萄化是capivasertib的主要代谢途径.
相关概念视频
Bioavailability: Overview
Clinical Trials: Overview
Methods for Studying Drug Absorption: In vitro
The diffusion cell method uses a two-compartment cell, including a donor compartment with the drug solution, which simulates the environment where the drug is applied, and a receptor compartment with a buffer solution, which simulates the environment...
Factors Influencing Drug Absorption: Presystemic Elimination
Factors Influencing Bioavailability: First-Pass Elimination
Methods for Studying Drug Absorption: In situ
The Doluisio method involves perfusing a prepared segment of a rat's small intestine with a solution of radiolabeled drug and a non-absorbable marker. This helps to differentiate between absorbed and non-absorbed drug concentrations. The intestinal segment is connected at both ends using tubing and syringes,...


![Technical Aspect of the Automated Synthesis and Real-Time Kinetic Evaluation of [11C]SNAP-7941](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F59557.jpg&w=3840&q=50)